Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Scenic Biotech, an international collaboration between Oxford University and Netherlands Cancer Institute, aims to unlock genetic potential in tackling cancer and other diseases with new funding.

Scenic Biotech BV, an international collaboration from Oxford University and the Netherlands Cancer Institute (NKI) that looks to tackle diseases on the genetic level, has secured a substantial amount in early stage funding to advance its immunotherapy technologies.

The therapeutics spinout company raised €6.5m in Series A financing, which will be used to develop its ‘genetic off-switch’ for cancer and rare genetic diseases. The round was co-led by Netherlands-based life sciences investor BioGeneration Ventures (BGV) and peer INKEF Capital, with the participation of Oxford Sciences Innovation (OSI), the university venturing investor for Oxford University.

Read more (Oxford University Innovation website)